The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ORGANIZATION
ORGANIZATION
- Generic Association Focuses on Pre-symptomatic/Preventive Care and Overseas Expansion in “Post-80% Era”
October 2, 2019
- Generic Use Rate at 75.8% in April-June: JGA
September 27, 2019
- Janssen’s Chris Hourigan Succeeds Jonsson as PhRMA Japan Chair
September 26, 2019
- EFPIA Japan Stresses Safety First and Need for Doctors’ Support on Delisting of OTC-Like Drugs, Notes Good Examples Overseas
September 25, 2019
- FPMAJ Sets Up New Taskforce to Promote Access to Japanese Drugs in Asia
September 24, 2019
- Nearly 80% of Japanese Support Insurance Coverage for High-Priced Drugs: Nonprofit Survey
September 18, 2019
- Strengthening Regulatory Science Will Accelerate Innovation in Drug Discovery: JPMA President
September 10, 2019
- Bristol-Myers CEO Caforio Named New PhRMA Chair, Tokyo Visit in October
September 6, 2019
- Number of Sales Reps in Japan Falls Below 60,000 in FY2018, Records 5 Consecutive Years of Decline
August 30, 2019
- Japan Doctors’ Group Raps Payer Proposal to Scrap Coverage for Pollen Allergy Drugs
August 29, 2019
- Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen
August 26, 2019
- Lab Test Group Seeks Better Reimbursement Rules for Cancer Gene Panel Testing
August 21, 2019
- Sales Rose Only Slightly, but Drug Wholesalers Still Improved Profit Rates in FY2018: JPWA
August 16, 2019
- Experts Talk over Biosimilar Challenges, Chide Unstable Supplies and Indication Gaps
July 19, 2019
- OTC Groups Call for Enhancing Self-Medication Tax Break, Submit Request
July 19, 2019
- Towards 2020 Reform, JPMA Wants Its Three-Pronged Proposal to Resonate with Public
July 17, 2019
- FPMAJ Asks Member Drug Makers to Conduct Self-Inspections to Ensure Stable Supplies
July 11, 2019
- Generic Association Aims to Contribute to Pre-Symptomatic and Preventive Care: New Industry Vision
July 9, 2019
- JPMA Pushing Teleworking for Member Companies
July 5, 2019
- Generic Use Rate at 74.0% in FY2018: JGA
July 1, 2019
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…